decitabine s.k
k.s.kim international (sk- pharma) ltd., israel - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - decitabine s.k. is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. decitabine s.k. is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy
decitabine medomie
medomie pharma ltd, israel - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg - decitabine - decitabine medomie is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy.
dacogen
j-c health care ltd - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - decitabine - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. dacogen is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy.
inqovi 35/100 decitabine 35 mg and cedazuridine 100 mg tablet blister pack
otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).
inqovi 35/100 decitabine 35 mg and cedazuridine 100 mg tablet bottle
otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).
decitabine spc 50mg for injection powder for solution for infusion
sudair pharma company, saudi arabia - decitabine - powder for solution for infusion - 50 mg
dacogen (decitabine) 50 mg powder for concentrate for solution for infusion
johnson & johnson sdn bhd - decitabine -
redtibin (decitabine) powder for injection 50mgvial
dr. reddy`s laboratories malaysia sdn. bhd. - decitabine -
dacogen (decitabine) 50 mg powder for concentrate for solution for infusion
johnson & johnson sdn. bhd. - decitabine -
decitas (decitabine 50mgvial powder for concentrate for solution for infusion)
accord healthcare sdn.bhd. - decitabine -